Peter Liljeström Group

Vaccines and Immunity

We are developing new vaccines against infectious diseases and are studying the immune mechanisms underlying protective immune responses. In this context, we study both innate and adaptive immune responses generated by various types of vaccines. We also build molecular vaccine vehicles and here one of the most central vaccine technologies is our alphavirus RNA replicon system developed in-house. Using this generic vaccine platform has allowed us to design different kinds of vaccines where vaccines can be delivered as naked DNA (DREP), naked RNA (RREP) or as viral particles (VREP).

We have also combined different vaccine technologies in so called prime-boost regimens in order to optimize the immune responses to various antigens. We have found that there are significant differences between viral vector vaccines, in particular how these vaccines generate responses in terms of quality, memory and recall capacity.

The past 4 years we have been part of three EU research networks involved in vaccine development against Chikungunya virus (CHIKV), Human immunodeficiency virus (HIV-1) and Tuberculosis (TB). Vaccine candidates against CHIKV and HIV-1 are now in clinical trials. Apart from these diseases we have also developed DREP vaccine candidates against the Zaire and Sudan Ebola viruses


Contact Address

Department of Microbiology, Tumor and Cell Biology
Karolinska Institutet
P.O. Box 280 (mail)
Nobels Väg 16 (visitors)
S-171 77 Stockholm, Sweden


Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
Lázaro-Frías A, Gómez-Medina S, Sánchez-Sampedro L, Ljungberg K, Ustav M, Liljeström P, et al
J. Virol. 2018 06;92(11):

Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes.
Zhu J, Powis de Tenbossche C, Cané S, Colau D, van Baren N, Lurquin C, et al
Nat Commun 2017 Nov;8(1):1404

Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus.
Roques P, Ljungberg K, Kümmerer B, Gosse L, Dereuddre-Bosquet N, Tchitchek N, et al
JCI Insight 2017 Mar;2(6):e83527

T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates.
Rollier C, Verschoor E, Verstrepen B, Drexhage J, Paranhos-Baccala G, Liljeström P, et al
Gene Ther. 2016 10;23(10):753-759

H1N1 influenza virus induces narcolepsy-like sleep disruption and targets sleep-wake regulatory neurons in mice.
Tesoriero C, Codita A, Zhang M, Cherninsky A, Karlsson H, Grassi-Zucconi G, et al
Proc. Natl. Acad. Sci. U.S.A. 2016 Jan;113(3):E368-77

A coordinated cross-disciplinary research initiative to address an increased incidence of narcolepsy following the 2009-2010 Pandemrix vaccination programme in Sweden.
Feltelius N, Persson I, Ahlqvist-Rastad J, Andersson M, Arnheim-Dahlström L, Bergman P, et al
J. Intern. Med. 2015 Oct;278(4):335-53

Humoral responses to HIVconsv induced by heterologous vaccine modalities in rhesus macaques.
Borthwick N, Rosario M, Schiffner T, Bowles E, Ahmed T, Liljeström P, et al
Immun Inflamm Dis 2015 Jun;3(2):82-93

Modification of a salmonid alphavirus replicon vector for enhanced expression of heterologous antigens.
Guo T, Johansson D, Liljeström P, Evensen , Haugland
J. Gen. Virol. 2015 Mar;96(Pt 3):565-70

Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen.
Knudsen M, Ljungberg K, Tatoud R, Weber J, Esteban M, Liljeström P
PLoS ONE 2015 ;10(2):e0117042

Self-replicating alphavirus RNA vaccines.
Ljungberg K, Liljeström P
Expert Rev Vaccines 2015 Feb;14(2):177-94

Modification of a salmonid alphavirus replicon vector for enhanced expression of heterologous antigens.
Guo T, Johansson D, Liljeström P, Evensen , Haugland
J. Gen. Virol. 2015 Mar;96(Pt 3):565-70

Self-replicating alphavirus RNA vaccines.
Ljungberg K, Liljeström P
Expert Rev Vaccines 2015 Feb;14(2):177-94

Prime-boost immunization strategies against Chikungunya virus.
Hallengärd D, Lum F, Kümmerer B, Lulla A, Lulla V, García-Arriaza J, et al
J. Virol. 2014 Nov;88(22):13333-43

Kinetic and phenotypic analysis of CD8+ T cell responses after priming with alphavirus replicons and homologous or heterologous booster immunizations.
Knudsen M, Ljungberg K, Kakoulidou M, Kostic L, Hallengärd D, García-Arriaza J, et al
J. Virol. 2014 Nov;88(21):12438-51

Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice.
Hallengärd D, Kakoulidou M, Lulla A, Kümmerer B, Johansson D, Mutso M, et al
J. Virol. 2014 Mar;88(5):2858-66

The adjuvant activity of alphavirus replicons is enhanced by incorporating the microbial molecule flagellin into the replicon.
Knudsen M, Johansson D, Kostic L, Nordström E, Tegerstedt K, Pasetto A, et al
PLoS ONE 2013 ;8(6):e65964

Host gene expression signatures discriminate between ferrets infected with genetically similar H1N1 strains.
Ljungberg K, McBrayer A, Camp J, Chu Y, Tapp R, Noah D, et al
PLoS ONE 2012 ;7(7):e40743

De-novo transcriptome sequencing of a normalized cDNA pool from influenza infected ferrets.
Camp J, Svensson T, McBrayer A, Jonsson C, Liljeström P, Bruder C
PLoS ONE 2012 ;7(5):e37104

Differential impact of interferon regulatory factor 7 in initiation of the type I interferon response in the lymphocytic choriomeningitis virus-infected central nervous system versus the periphery.
Christensen J, Fenger C, Issazadeh-Navikas S, Krug A, Liljestrøm P, Goriely S, et al
J. Virol. 2012 Jul;86(13):7384-92

Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to that with conventional plasmid DNA vaccine.
Knudsen M, Mbewe-Mvula A, Rosario M, Johansson D, Kakoulidou M, Bridgeman A, et al
J. Virol. 2012 Apr;86(8):4082-90

Intradermal electroporation of naked replicon RNA elicits strong immune responses.
Johansson D, Ljungberg K, Kakoulidou M, Liljeström P
PLoS ONE 2012 ;7(1):e29732

Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).
García F, Bernaldo de Quirós J, Gómez C, Perdiguero B, Nájera J, Jiménez V, et al
Vaccine 2011 Oct;29(46):8309-16

Role of innate signalling pathways in the immunogenicity of alphaviral replicon-based vaccines.
Näslund T, Kostic L, Nordström E, Chen M, Liljeström P
Virol. J. 2011 Jan;8():36


Publications 1990-2010

Publications 2004-2010 (pdf)

Publications 1990-2003 (Pdf file, 87 Kb)

Group Members

Peter LiljeströmProfessor

08-524 859 90

Karl LjungbergSenior lab manager

Inga SzurgotPostdoc